CJC-1295 (a long-acting GHRH analog, DAC-modified) and Ipamorelin (a selective GHSR-1a agonist) are co-utilized in endocrine research to amplify physiologic, pulse-based growth hormone (GH) release with downstream IGF-1 signaling. The combination targets complementary receptors within the hypothalamic–pituitary axis to support investigations in tissue remodeling, body-composition regulation, metabolic efficiency, sleep architecture, and neuroendocrine homeostasis, while preserving native feedback dynamics.
CJC-1295 → GHRH-R: Prolonged receptor engagement enhances cAMP-mediated GH synthesis in anterior pituitary somatotrophs.
Ipamorelin → GHSR-1a: Ghrelin-mimetic signaling triggers Ca2+-dependent GH release with high receptor selectivity and minimal
off-target endocrine activity (e.g., limited prolactin/cortisol elevation).
Combined effect: Coordinated GH pulse amplitude/frequency→ downstream IGF-1 signaling supporting protein turnover, connective-tissue dynamics,
and systemic recovery paradigms in research settings.
Somatotropic axis modulation • Skeletal muscle/connective-tissue models • Energy substrate utilization and lipolysis inquiry • Sleep/circadian GH rhythm characterization • Exploratory studies of age-associated endocrine decline and recovery kinetics.
Revitalized Health peptides are produced under cGMP-aligned conditions using pharmaceutical-grade inputs. Each lot is confirmed at ≥99% purity via HPLC with LC-MS/MS identity, and is assessed for appearance, solubility, and microbial quality; endotoxin limits are monitored to research-grade specifications. Certificates of Analysis are issued for every batch to document traceability and analytical results.
Store lyophilized vials at 2–8 °C, protected from light and moisture. After reconstitution with bacteriostatic water, maintain at 2–8 °C and utilize within 20 days. Avoid repeated freeze–thaw cycles to preserve peptide integrity and receptor-binding fidelity.
For laboratory research use only. Not for human consumption, therapeutic, or diagnostic purposes. Supplied exclusively to qualified professionals conducting controlled scientific studies.
Formulated for research applications. Purity, identity, and lot analytics available per batch. Not medical advice.
Identity: CJC-1295 with Drug Affinity Complex (DAC); long-acting GHRH analog that extends exposure via albumin interactions.
Mode: Stimulates pituitary somatotrophs through GHRH receptor → ↑ GH pulse amplitude/frequency → hepatic/extrahepatic IGF-1 upregulation; downstream effects on protein synthesis, lipolysis, and recovery markers.
Analytics: HPLC/LC-MS identity/purity; peptide content; sterility/endotoxin for parenterals; stability. PD: GH profiling (pulsatility), serum IGF-1/IGFBP-3, fasting glucose/insulin, body composition (DXA), sleep quality and recovery logs. Monitoring: edema, carpal-tunnel-like paresthesias, ISR.
Identity: Ipamorelin, selective ghrelin receptor (GHSR-1a) agonist with minimal prolactin/cortisol effects vs. first-gen GHSs.
Mode: Triggers GH release via hypothalamic/pituitary GHSR with low endocrine “noise,” complementing GHRH-pathway agents; supports pulsatile GH without large IGF-1 spikes alone—pairs well with GHRH analogs.
Analytics: HPLC/LC-MS identity/purity; sterility/endotoxin where applicable; stability. PD: GH secretory profiles, IGF-1, sleep metrics, recovery surveys. Monitoring: ISR, transient hunger/lightheadedness in sensitive users.
CJC-1295 (DAC) + Ipamorelin: dual-axis GH support—GHRH receptor stimulation (CJC) increases pulse amplitude and IGF-1 tone, while GHSR agonism (Ipamorelin) increases pulse frequency with a clean endocrine profile. This pairing seeks more physiologic GH pulsatility with complementary PK (longer-acting CJC + shorter-acting Ipamorelin). Educational content; not medical advice.